Characterization of a novel single-chain bispecific antibody for retargeting of T Cells to tumor cells via the TCR co-receptor CD8

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Michalk, Irene ^a   Feldmann, Anja ^a,b   Koristka, Stefanie ^a   Arndt, Claudia ^a   Cartellieri, Marc ^a,b   Ehninger, Armin ^a,c   Ehninger, Gerhard ^c   Bachmann, Michael P ^a,b,d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; CD8 ANTIGEN; CD8 MB1 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CROSS LINKING REAGENT; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; DRUG SPECIFICITY; EMBRYO; HUMAN; HUMAN CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL DESTRUCTION; ANIMAL; CELL LINE; CELL SEPARATION; CYTOTOXICITY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL SEPARATION; CROSS-LINKING REAGENTS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; SINGLE-CHAIN ANTIBODIES;

EID: 84899688977     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095517     Document Type: Article

References (25)

1. Kharfan-Dabaja MA, Hamadani M, Reljic T, Pyngolil R, Komrokji RS, et al. (2013) Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol 163: 315-325. doi: 10.1111/bjh.12528.
2. 13Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells. Nucl Med Biol 241: 68-76. doi: 10.1016/j.nucmedbio.2013.09.010.
3. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, et al. (2010) Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2: 309-319.
4. Müller D, Kontermann RE. (2010) Bispecific antibodies for cancer immunotherapy: Current perspectives. BioDrugs 24: 89-98. doi: 10.2165/11530960-000000000-00000.
5. Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, et al. (2012) Cancer immunotherapy by retargeting of immune effector cells via recombinant bispecific antibody constructs. Antibodies 1: 172-198.
6. Byrne H, Conroy PJ, Whisstock JC, O'Kennedy RJ. (2013) A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31: 621-632.
7. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, et al. (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3- bispecific single-chain antibody construct. Int J Cancer 115: 98-104. (Pubitemid 40559673)
8. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. (2006) Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 43: 763-771. (Pubitemid 41785405)
9. Baeuerle PA, Reinhardt C (2009) Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 69: 4941-4944.
10. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, et al. (2012) Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 423: 261-268.
11. Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136: 334-342.
12. Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, et al. (2013) Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun 42: 05-16. doi: 10.1016/j.jaut.2013.01.002. Epub 2013 Jan 22.
13. Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen EM, et al. (2013) Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia Aug 20. doi: 10.1038/leu.2013.243. Epub.
14. Feldmann A, Stamova S, Bippes CC, Bartsch H, Wehner R, et al. (2011) Retargeting of T cells to prostate stem cell antigen expressing tumor cells: comparison of different antibody formats. Prostate 71: 998-1011.
15. Feldmann A, Arndt C, Töpfer K, Stamova S, Krone F, et al. (2012) Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol 189: 3249-3259.
16. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, et al. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 170: 4397-4402. (Pubitemid 36428210)
17. Pörtner LM, Schönberg K, Hejazi M, Brünnert D, Neumann F, et al. (2012) T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19xCD3 or CD19xCD16. Cancer Immunol Immunother Oct;61(10): 1869-1875. Epub 2012 Sep 14.
18. Arndt C, von Bonin, M Cartellieri, M Feldmann, A Koristka, S, etal. (2013) Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 27[4]: 964-967.
19. Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, et al. (2011) Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. Leukemia: 25[6]: 1053-1056.
20. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ (2004) Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood Nov 1;104(9): 840-848. Epub 2004 Jul 6.
21. Cunha AC, Weigle B, Kiessling A, Bachmann M, Rieber EP (2006) Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. Cancer Lett 236: 229-238.
22. Bippes CC, Feldmann A, Stamova S, Cartellieri M, Schwarzer A, et al. (2011) A novel modular antigen delivery system for immuno targeting of human 6-sulfo LacNAc-positive blood dendritic cells (SlanDCs). PLoS One Jan 21;6(1): e16315. doi: 10.1371/journal.pone.0016315.
23. Morgenroth A, Cartellieri M, Schmitz M, Gunes S, Weigle B, et al. (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67[10]: 1121-1131. (Pubitemid 46983341)
24. Bartsch H, Bachmann M (2009) Sequential use of immunoblots for characterization of autoantibody specificities. Methods Mol Biol 536: 293-298. doi: 10.1007/978-1-59745-542-8-31.
25. Arndt C, Koristka S, Feldmann A, Bartsch H, Bachmann M (2012) Coomassie-Brilliant Blue staining of polyacrylamide gels. Methods Mol Biol: 869: 465-469. doi: 10.1007/978-1-61779-821-4-40. PMID: 22585511[PubMed - indexed for MEDLINE].